NUPLAZID net product sales in the range of $685 to $695 million, compared with the prior guidance range of $665 to $690 million. DAYBUE net product sales in the range of $385 to $400 million, compared with the prior guidance range of $380 to $405 million. R&D expense in the range of $335 to $345 million, compared with the prior guidance range of $330 to $350 million. SG&A expense in the range of $540 to $555 million, compared with the prior guidance range of $535 to $565 million.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACAD:
- ACAD Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- ACADIA Pharmaceuticals Advances Alzheimer’s Disease Psychosis Study with ACP-204
- ACADIA Pharmaceuticals Advances Phase 2 Study of ACP-204 for Lewy Body Dementia Psychosis
- ACADIA’s ACP-204 Study: A Promising Step for Alzheimer’s Disease Psychosis Treatment
- ACADIA Pharmaceuticals Advances Phase 3 Study for Lewy Body Dementia Psychosis Treatment